Tampere University Hospital | Tampere Heart Hospital
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with diffuse large B-cell lymphoma (DLBCL) that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin [R-GemOx], or bendamustine + rituximab [BR]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT).
Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously.
Trial details include:
The trial duration will be up to 5 years.
All trial participants have a 21-day screening period, a treatment period, and a follow-up period that continues until death.
The estimated trial duration for an individual subject depends upon the treatment arm assigned:
Participants who receive epcoritamab will have 28-day treatment cycles. Epcoritamab will be given once weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse events.
Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either:
Full description
The trial is an open label, multi-center, global phase-3 randomized trial of epcoritamab. The goal of this randomized trial is to evaluate the efficacy of epcoritamab (GEN3013, DuoBody®-CD3xCD20) compared to investigator's choice of chemotherapy, in patients with relapsed, refractory DLBCL who have failed or are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). No change in chemotherapy is permitted for participants during the treatment phase of the trial.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Main Inclusion Criteria:
Relapsed or refractory disease and previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since lymphoma diagnosis
One of the confirmed histologies below with CD20-positivity:
ECOG PS score of 0-2
Failed previous HDT-ASCT or not eligible for HDT-ASCT at screening
Patients must have detectable disease by PET scan and measurable by CT scan or MRI
Acceptable renal and liver function
Life expectancy >2 months on SOC treatment
Main Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
552 participants in 2 patient groups
Loading...
Central trial contact
Genmab A/S Trial Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal